Want to see SRRK full AI Analyst Report?
SRRK Stock Chart & Stats
$47.67
-$1.81(-3.66%)
At close: 4:00 PM EDT
$47.67
-$1.81(-3.66%)
Day’s Range― - ―
52-Week Range$27.07 - $58.49
Previous Close$47.67
Volume838.71K
Average Volume (3M)1.53M
Market Cap
$5.86B
Enterprise Value$5.98K
Total Cash (Recent Filing)$479.94M
Total Debt (Recent Filing)$205.67M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 06, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.45
Shares Outstanding119,828,340
10 Day Avg. Volume1,038,028
30 Day Avg. Volume1,529,778
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$59.56Price Target Upside24.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$6.27M
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone (BLA Acceptance)BLA acceptance with a defined PDUFA date materially reduces regulatory timing uncertainty and, if approved, would convert Scholar Rock from a pure R&D sponsor to a commercial-stage company. This validation improves partner negotiation leverage, de-risks key SMA program and underpins multi-quarter planning for launch and reimbursement.
Strong Cash Position And Financing OptionalityA sizable cash balance plus access to additional debt, ATM proceeds and a potential PRV monetization provide durable runway into the approval window and initial commercialization. These financing levers reduce immediate liquidity-driven execution risk and give management optionality to fund launch investments without immediate product income.
Commercial Launch Readiness And Distribution ReachEstablished commercial infrastructure and partner networks create a durable go-to-market advantage at launch, lowering time-to-patient and incremental sales costs. Pre-built payer/provider engagement and specialty pharmacy integration meaningfully improve the company's ability to convert approval into uptake across a concentrated SMA treatment community.
Bears Say
Large, Persistent Cash BurnSustained negative operating and free cash flow at this scale indicates the business consumes significant capital each year. Even with financing sources, prolonged burn raises the risk of dilution or constrained investment if commercial revenue is delayed, pressuring long-term financial flexibility and strategic choices.
Rising Debt And LeverageMaterial increase in debt and higher leverage reduces balance sheet flexibility and raises fixed obligations. Higher indebtedness limits optionality for opportunistic R&D or marketing spend, can increase financing costs, and magnifies downside if expected product approvals or launches slip beyond planning horizons.
No Product Revenue; Reliance On External FinancingWithout product sales, the company depends on capital markets, debt and one-off monetizations to fund operations and a launch. This structural dependency increases dilution and execution risk if market access, label scope or payer uptake is slower than expected, limiting enduring financial resilience until products generate recurring revenue.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding’s price range in the past 12 months?
Scholar Rock Holding lowest stock price was $27.07 and its highest was $58.49 in the past 12 months.
What is Scholar Rock Holding’s market cap?
Scholar Rock Holding’s market cap is $5.86B.
When is Scholar Rock Holding’s upcoming earnings report date?
Scholar Rock Holding’s upcoming earnings report date is Aug 06, 2026 which is in 7 days.
How were Scholar Rock Holding’s earnings last quarter?
Scholar Rock Holding released its earnings results on May 07, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.8 by -$0.03.
Is Scholar Rock Holding overvalued?
According to Wall Street analysts Scholar Rock Holding’s price is currently Undervalued.
Does Scholar Rock Holding pay dividends?
Scholar Rock Holding does not currently pay dividends.
What is Scholar Rock Holding’s EPS estimate?
Scholar Rock Holding’s EPS estimate is -0.84.
How many shares outstanding does Scholar Rock Holding have?
Scholar Rock Holding has 119,828,340 shares outstanding.
What happened to Scholar Rock Holding’s price movement after its last earnings report?
Scholar Rock Holding reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.8. Following the earnings report the stock price went down -1.401%.
Which hedge fund is a major shareholder of Scholar Rock Holding?
Currently, no hedge funds are holding shares in SRRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.56 (24.93% Upside)
$59.56 (24.93% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 183.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 12.8%
Last 30 Days ▼ 12.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.33%
Trailing 12-Months
Company Description
Scholar Rock Holding
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
SRRK Company Deck
SRRK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: FDA accepted the BLA with a clear PDUFA date (Sept 30, 2026), the company has created dual manufacturing paths (second facility supplying product in early Q3), European review appears on track for midyear, and the balance sheet and commercial infrastructure were strengthened during the quarter. Key risks remain focused on regulatory classification of the Catalent Indiana site, continued manufacturing/regulatory uncertainty until that classification, high pre-commercial operating spend, and the need to monetize financing levers (debt/ATM/PRV). On balance, the material positive developments (BLA acceptance, dual fill-finish strategy, clear supply path, strong cash position, pipeline progression and commercial readiness) outweigh the remaining lowlights and uncertainties.View all SRRK earnings summariesSRRK Stock 12 Month Forecast
Average Price Target
$59.56
▲(24.93% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
20.63% Insiders
30.07% Mutual Funds
0.64% Other Institutional Investors
36.31% Public Companies and
Individual Investors